Solace Eczema Cream To Be Sold as OTC Product in US

Resilia Pharmaceuticals, Inc. has signed a license agreement with Holland, MI-based Pelle Ventures, LLC that gives Resilia the rights to make, market and sell Solace Eczema Cream as an OTC product in the US.

Financial terms of the transaction were not disclosed.

Previously only available by prescription, Solace Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin building blocks like cholesterol, fatty acids, and ceramides to help reduce the likelihood of environmental triggers causing eczema symptoms; as well as employing palmitamide MEA (PEA), a natural endogenous fatty acid to help relieve itchy, dry skin often associated with eczema.

The pandemic has impacted production of the topical treatment, according to company officials.

“Covid-19 has really impacted the availability of certain manufacturing components for the pharma industry. As a result, Solace Cream was recently unavailable, but Resilia is working hard to get the product back on the market in the coming months,” said Andrew Shales, CEO of Resilia.

“We are delighted to add Solace Cream to the Resilia portfolio of dermatology products, said Harsha Murthy, executive chairman of the board of directors at Resilia Pharmaceuticals. “Much is unknown about the causes of eczema, but we do know that eczema has a profound impact on the quality of life in those patients who suffer from its symptoms. Resilia is proud to be able to offer patients an effective and safe product like Solace Cream, a product previously available only by prescription. Solace Cream fits squarely within Resilia's mission to bring patients high-quality products at reasonable prices.”

Solace Cream is said to repair and restore the skin barrier and keep eczema in remission up to 48% longer and reduce average weekly steroid applications by 62%.

Solace Cream will be sold through Amazon, according to the company. 

Headquartered in Atlanta, Resilia Pharmaceuticals' product line consists of Recedo topical gel, which is leading prescribed Rx scar treatment; Ecoza (econazole nitrate) topical foam, 1%; and Neocera, a version of Neosalus formulated with ceramides.